

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 1, 2018

NEKTAR THERAPEUTICS

(Exact Name of Registrant as Specified in Charter)

**Delaware
(State or Other Jurisdiction
of Incorporation)**

**0-24006
(Commission
File Number)**

**94-3134940
(IRS Employer
Identification No.)**

**455 Mission Bay Boulevard South
San Francisco, California 94158
(Address of Principal Executive Offices and Zip Code)**

Registrant's telephone number, including area code: (415) 482-5300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On March 1, 2018, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter and year ended December 31, 2017. A copy of the Press Release is furnished herewith as Exhibit 99.1.

On February 21, 2018, Nektar announced that it would hold a Webcast conference call on March 1, 2018 to review its financial results for the quarter and year ended December 31, 2017. This conference call is accessible through a link that is posted on the home page and Investors section of the Nektar website: <http://www.nektar.com>.

The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar Therapeutics, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
<u>99.1</u>	<u>Press release titled “Nektar Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results” issued by Nektar Therapeutics on March 1, 2018.</u>

SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

By: /s/ Mark A. Wilson
Mark A. Wilson
General Counsel and Secretary

Date: March 1, 2018

Nektar Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results

SAN FRANCISCO, March 1, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2017.

Cash and investments in marketable securities at December 31, 2017 were \$353.2 million as compared to \$389.1 million at December 31, 2016. This does not include \$1.85 billion in upfront payments from the new Bristol-Myers Squibb collaboration, which was announced on February 14, 2018.

“This past year was truly transformational for Nektar as we achieved a number of successes with Nektar medicines across our three key therapeutic areas of immuno-oncology, immunology and pain,” said Howard W. Robin, President and Chief Executive Officer of Nektar. “In the area of pain, we completed a successful Phase 3 program for NKTR-181 in over 2,100 patients and healthy volunteers that will comprise our NDA submission in the second quarter of this year. In immunology, we entered into a major partnership with Eli Lilly for NKTR-358, a potential first-in-class T regulatory resolution therapeutic, which will be developed to treat a broad range of auto-immune disorders. Finally, in immuno-oncology, the clinical success we achieved with NKTR-214 led to a groundbreaking collaboration with Bristol-Myers Squibb that now enables us to broadly and rapidly advance NKTR-214 into over 20 registrational trials in up to 15,000 patients.”

Summary of Financial Results

Revenue for the fourth quarter of 2017 was \$95.5 million as compared to \$37.5 million in the fourth quarter of 2016. Revenue in the fourth quarter of 2017 included a total of \$60.0 million of non-recurring revenue related to a new sublicense agreement, a contract settlement agreement and the recognition of deferred revenue from several collaboration agreements.

Revenue for the year ended December 31, 2017 was \$307.7 million as compared to \$165.4 million in 2016. Revenue in 2017 included recognition of \$130.1 million of the \$150.0 million upfront payment from Nektar’s collaboration with Eli Lilly & Company for the development and commercialization of NKTR-358.

Total operating costs and expenses in the fourth quarter of 2017 were \$119.5 million as compared to \$69.6 million in the fourth quarter of 2016. Total operating costs and expenses increased primarily as a result of higher research and development (R&D) expense. Total operating costs and expenses for the year ended December 31, 2017 were \$367.4 million as compared to \$278.3 million in 2016.

R&D expense in the fourth quarter of 2017 was \$81.4 million as compared to \$50.2 million for the fourth quarter of 2016. R&D expense for the year ended December 31, 2017 was \$268.5 million as compared to \$203.8 million in 2016. R&D expense was higher in 2017 as compared to 2016 primarily because of expenses for our pipeline programs, including the completion of Phase 3 clinical studies for NKTR-181, Phase 1/2 clinical studies of NKTR-214 and NKTR-358, and IND-enabling activities for NKTR-262 and NKTR-255.

General and administrative (G&A) expense was \$12.3 million in the fourth quarter of 2017 as compared to \$12.8 million in the fourth quarter of 2016. G&A expense for the year ended December 31, 2017 was \$52.4 million as compared to \$44.3 million in 2016.

Net loss for the fourth quarter of 2017 was \$33.8 million or \$0.21 loss per share as compared to a net loss of \$42.2 million or \$0.28 loss per share in the fourth quarter of 2016. Net loss for the year ended December 31, 2017 was \$96.7 million or \$0.62 loss per share as compared to a net loss of \$153.5 million or \$1.10 loss per share in 2016.

2017 and Year-to-Date Business Highlights

- In February 2018, Nektar and Bristol-Myers Squibb entered into a global development and commercialization agreement to evaluate the full potential of NKTR-214 plus Opdivo® (nivolumab) in more than 20 indications in 9 tumor types including melanoma, renal cell carcinoma, non-small cell lung cancer, bladder and triple negative breast cancer. The first pivotal studies in melanoma and renal cell carcinoma are expected to be initiated in mid-2018.
- In December 2017, Nektar submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NKTR-262, a small molecule agonist that targets toll-like receptors (TLRs) found on innate immune cells in the body. The REVEAL Phase 1/2 study will evaluate the safety, tolerability and anti-tumor effect of NKTR-262, administered in combination with NKTR-214 (doublet) and in combination with NKTR-214 and nivolumab (triplet), in patients with locally advanced or metastatic cancers. The company plans to enroll the first patients in the REVEAL study in March of 2018.
- In November 2017, Nektar announced positive data from the dose-escalation stage of the PIVOT-02 study of NKTR-214 in combination with Opdivo at the 2017 SITC conference. Results showed compelling response rates and favorable safety data in both PD-L1 negative and PD-L1 positive patients with melanoma, renal cell carcinoma and non-small cell lung cancer.
- In September 2017, Nektar initiated the PROPEL clinical study to evaluate the efficacy and safety of NKTR-214 in combination with approved checkpoint inhibitors, TECENTRIQ® (atezolizumab) and KEYTRUDA® (pembrolizumab) in patients with bladder and non-small cell lung cancer. Data from the PROPEL study is expected in the second half of 2018.
- In July 2017, Nektar and Eli Lilly announced a strategic collaboration to develop and commercialize NKTR-358, a potential first-in-class resolution therapeutic, that addresses an underlying immune system imbalance in patients with auto-immune conditions. A Phase 1 single-ascending dose study is underway and a Phase 1/2 multiple-ascending dose study of NKTR-358 in patients with lupus is planned to begin in the second quarter of 2018.
- In July 2017, Nektar announced positive results from a Human Abuse Potential (HAP) study of NKTR-181, a first-in-class opioid analgesic.
- In May 2017, Nektar announced a new research collaboration with Takeda to explore the combination of NKTR-214 with five oncology compounds from Takeda's cancer portfolio including a SYK-inhibitor and a proteasome inhibitor.
- In March 2017, Nektar announced positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181 in over 600 patients with chronic low back pain. The primary efficacy endpoint of the study demonstrated significantly improved chronic back pain relief with NKTR-181 compared to placebo (p=0.0019). Key secondary endpoints of the study also achieved high statistical significance. The study demonstrated that NKTR-181 had a favorable safety profile and was well tolerated.

The company also announced upcoming presentations at the following scientific congresses during the first half of 2018:

American Association for Cancer Research (AACR) Annual Meeting 2018, Chicago, IL:

- **Abstract 3755/Poster 5:** “Comprehensive antitumor immune activation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214”, Kivimae, S., et al.
 - **Session:** Immunology: Immunomodulatory Agents and Interventions 1
 - **Session Date and Time:** Tuesday, April 17, 2018, 8:00 a.m. - 12:00 p.m. Central Time
 - **Location:** McCormick Place South, Exhibit Hall A, Poster Section 32
 - **Abstract 2755/Poster 17:** “NKTR-262: Prodrug pharmacokinetics in mice, rats, and dogs”, Lee, M., et al.
 - **Session:** Immunology: Immune Mechanisms Invoked by Therapies 1
 - **Session Date and Time:** Monday, April 16, 2018, 1:00 p.m. - 5:00 p.m. Central Time
 - **Location:** McCormick Place South, Exhibit Hall A, Poster Section 33
 - **Abstract 123/Poster 13:** “Enhanced anti-tumor activity of the combination of entinostat and NKTR-214 in renal and colon cancer tumor models”, Wang, L., et al.
 - **Session:** Tumor Biology: Role of the Innate Immune System in Tumorigenesis
 - **Session Date and Time:** Sunday, April 15, 2018, 1:00 p.m. - 5:00 p.m. Central Time
 - **Location:** McCormick Place South, Exhibit Hall A, Poster Section 5
 - **Abstract 3566/Poster 4:** “Enhanced expansion and tumor targeting of adoptively transferred T cells with NKTR-214”, Parisi, G., et al.
 - **Session:** Clinical Research: Adoptive Cell Therapy 3
 - **Session Date and Time:** Tuesday, April 17, 2018, 8:00 a.m. - 12:00 p.m. Central Time
 - **Location:** McCormick Place South, Exhibit Hall A, Poster Section 24
-

Antigen-Specific Immune Tolerance Drug Development Summit 2018, Boston, MA:

- **Preclinical Data Presentation:** *“NKTR-358: A Selective Regulatory T Cell Inducing Agent for the Treatment of Autoimmune and Inflammatory Diseases”*
 - **Presenter:** Jonathan Zalevsky, Ph.D., Nektar Therapeutics
 - **Date and Time:** Wednesday, April 25, 2018, 4:20 p.m. Eastern Time

American Academy of Pain Medicine 34th Annual Meeting, Vancouver, BC:

- **Poster:** *“Efficacy, safety, and tolerability of NKTR-181 in patients with moderate to severe chronic low-back pain: A Phase 3 study”*
 - **Presenter:** John Markman, M.D., University of Rochester Medical Center
 - **Session:** Poster Session 2
 - **Date and Time:** Friday, April 27, 2018, 6:00 p.m. Pacific Time
- **Poster:** *“Measuring withdrawal in a phase 3 study of a new analgesic, NKTR-181, in subjects with moderate-to-severe chronic low-back pain”*
 - **Presenter:** Jack Henningfield, Ph.D., Pinney Associates
 - **Session:** Poster Session 2
 - **Date:** Friday, April 27, 2018, 6:00 p.m. Pacific Time

Treg Directed Therapy for Autoimmune Disorders Meeting, Boston, MA:

- **Preclinical Data Presentation:** *“NKTR-358: An IL-2 Pathway Agonist that Selectively Expands and Activates Regulatory T cells for the Treatment of Allergy and Autoimmune Disease”*
 - **Presenter:** Jonathan Zalevsky, Ph.D., Nektar Therapeutics
 - **Session:** Enhanced Treg-based therapy with the use of IL-2
 - **Date and Time:** Wednesday, May 23, 2018, 3:40 p.m. Eastern Time

3rd Annual Advances in Immuno-Oncology Congress, London, U.K.:

- **Presentation:** *“Assessing The Potential Of An Immunotherapeutic Agent”*
 - **Presenter:** Jonathan Zalevsky, Ph.D., Nektar Therapeutics
 - **Session:** Translational Immuno-Oncology
 - **Date and Time:** Thursday, May 24, 2018, 5:40 p.m. London Time

College on Problems of Drug Dependence 80th Annual Scientific Meeting, San Diego, CA:

- **Oral Presentation:** *“Neuropharmacodynamic Profile of NKTR-181: Correlation to Low Abuse Potential”*
 - **Presenter:** Laurie VanderVeen, Ph.D., Nektar Therapeutics
 - **Session:** Preclinical Opioid
 - **Date and Time:** Tuesday, June 12, 2018, 10:15 a.m. - 10:30 a.m. Pacific Time
 - **Oral Presentation:** *“Assessment of Drug Abuse-Related Events with MADDERS in SUMMIT-07: A Phase-3 Study of NKTR-181 in Patients With Moderate to Severe Chronic Low-Back Pain”*
 - **Presenter:** Ryan K. Lanier, Ph.D., Analgesic Solutions
 - **Session:** Pain
 - **Date and Time:** Wednesday, June 13, 2018, 1:30 p.m. - 1:45 p.m. Pacific Time
-

Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial Results

Nektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time today, Thursday, March 1, 2018.

This press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investors section of the Nektar website: <http://ir.nektar.com/>. The web broadcast of the conference call will be available for replay through Monday, April 2, 2018.

To access the conference call, follow these instructions:

Dial: (877) 881.2183 (U.S.); (970) 315.0453 (international)
Passcode: 6299239 (Nektar Therapeutics is the host)

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investors page at the Nektar website as soon as practical after the conclusion of the conference call.

About Nektar Therapeutics

Nektar Therapeutics is a research-based biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at <http://www.nektar.com>.

Opdivo® is a registered trademark of Bristol-Myers Squibb, TECENTRIQ® is a registered trademark of Roche and KEYTRUDA® is a registered trademark of Merck.

Cautionary Note Regarding Forward-Looking Statements

This press release contains uncertain or forward-looking statements which can be identified by words such as: "could," "plan," "expect," "prepare," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the potential therapeutic benefits of and future development plans for our products (including NKTR-214, NKTR-181, NKTR-358, NKTR-262 and NKTR-255), the potential impact of NKTR-181 with respect to the opioid abuse epidemic, the timing and strategy for regulatory filings (including the timing and strategy for filing a new drug application, "NDA"), and the results of clinical trials. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements and you should not rely on such statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include: (i) clinical study outcomes remain very unpredictable and it is possible that a clinical study could fail even after positive interim data is observed; (ii) the regulatory pathway to review and approve pharmaceutical products is subject to substantial uncertainty; (iii) the data package required for filing and approval of an NDA to the FDA is very uncertain and difficult to predict due to broad FDA regulatory discretion, and changing FDA regulatory guidelines; (iv) the final outcomes and conclusions from sponsor meetings with FDA are subject to substantial FDA discretion associated with issuing final meeting minutes and outcomes; (v) regulations concerning and controlling access to opioid-based pharmaceuticals are strict and it is difficult to predict which scheduling category will apply to NKTR-181 if regulatory approval is achieved; (vi) the timing of regulatory approval for the recently announced strategic collaboration agreement with Bristol-Myers Squibb is uncertain; (vii) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (viii) certain other important risks and uncertainties set forth in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2018. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement.

Contact:

For Investors:
Jennifer Ruddock of Nektar Therapeutics
415-482-5585

Jodi Sievers of Nektar Therapeutics
415-482-5593

For Media:
Jennifer Paganelli
347-658-8290
jpaganelli@purecommunications.com

NEKTAR THERAPEUTICS
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)

ASSETS	December 31, 2017 ⁽¹⁾	December 31, 2016 ⁽¹⁾
Current assets:		
Cash and cash equivalents	\$ 4,762	\$ 59,640
Short-term investments	291,370	329,462
Accounts receivable, net	5,014	15,678
Inventory	10,726	11,109
Other current assets	14,948	10,063
Total current assets	326,820	425,952
Long-term investments	57,088	—
Property, plant and equipment, net	47,463	65,601
Goodwill	76,501	76,501
Other assets	994	817
Total assets	\$ 508,866	\$ 568,871
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 4,782	\$ 2,816
Accrued compensation	8,263	18,280
Accrued clinical trial expenses	9,461	7,958
Other accrued expenses	10,064	4,711
Interest payable	4,198	4,198
Liability related to refundable upfront payment	—	12,500
Deferred revenue, current portion	18,949	14,352
Other current liabilities	446	7,407
Total current liabilities	56,163	72,222
Senior secured notes, net	245,207	243,464
Liability related to the sale of future royalties, net	94,655	105,950
Deferred revenue, less current portion	19,021	51,887
Other long-term liabilities	5,992	7,223
Total liabilities	421,038	480,746
Commitments and contingencies		
Stockholders' equity:		
Preferred stock	—	—
Common stock	15	15
Capital in excess of par value	2,207,865	2,111,483
Accumulated other comprehensive loss	(2,111)	(2,363)
Accumulated deficit	(2,117,941)	(2,021,010)
Total stockholders' equity	87,828	88,125
Total liabilities and stockholders' equity	\$ 508,866	\$ 568,871

(1) The consolidated balance sheets at December 31, 2017 and 2016 have been derived from the audited financial statements at those dates but do not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements.

NEKTAR THERAPEUTICS
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share information)
(Unaudited)

	Three Months Ended December 31,		Year Ended December 31,	
	2017	2016	2017 ⁽¹⁾	2016 ⁽¹⁾
Revenue:				
Product sales	\$ 7,791	\$ 13,690	\$ 32,688	\$ 55,354
Royalty revenue	9,574	6,392	33,527	19,542
Non-cash royalty revenue related to sale of future royalties	9,164	7,817	30,531	30,158
License, collaboration and other revenue	68,937	9,553	210,965	60,382
Total revenue	95,466	37,452	307,711	165,436
Operating costs and expenses:				
Cost of goods sold	9,753	6,604	30,547	30,215
Research and development	81,429	50,232	268,461	203,801
General and administrative	12,337	12,760	52,364	44,275
Impairment of equipment and other costs for terminated program	15,981	—	15,981	—
Total operating costs and expenses	119,500	69,596	367,353	278,291
Loss from operations	(24,034)	(32,144)	(59,642)	(112,855)
Non-operating income (expense):				
Interest expense	(5,633)	(5,550)	(22,085)	(22,468)
Non-cash interest expense on liability related to sale of future royalties	(5,334)	(4,783)	(18,869)	(19,712)
Interest income and other income (expense), net	1,357	721	4,520	2,387
Total non-operating expense, net	(9,610)	(9,612)	(36,434)	(39,793)
Loss before provision for income taxes	(33,644)	(41,756)	(96,076)	(152,648)
Provision for income taxes	182	443	616	876
Net loss	\$ (33,826)	\$ (42,199)	\$ (96,692)	\$ (153,524)
Basic and diluted net loss per share	\$ (0.21)	\$ (0.28)	\$ (0.62)	\$ (1.10)
Weighted average shares outstanding used in computing basic and diluted net loss per share				
	158,324	149,071	155,953	139,596

(1) The consolidated statements of operations for the years ended December 31, 2017 and 2016 have been derived from the audited financial statements as of those dates but do not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements.

NEKTAR THERAPEUTICS
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)

	Year Ended December 31,	
	2017 ⁽¹⁾	2016 ⁽¹⁾
Cash flows from operating activities:		
Net loss	\$ (96,692)	\$ (153,524)
Adjustments to reconcile net loss to net cash used in operating activities:		
Non-cash royalty revenue related to sale of future royalties	(30,531)	(30,158)
Non-cash interest expense on liability related to sale of future royalties	18,869	19,712
Stock-based compensation	36,615	25,850
Depreciation and amortization	14,741	15,351
Impairment of equipment from terminated program	15,081	—
Other non-cash transactions	(881)	(2,185)
Changes in operating assets and liabilities:		
Accounts receivable, net	10,664	4,269
Inventory	383	237
Other assets	(4,800)	(312)
Accounts payable	2,074	518
Accrued compensation	(10,017)	12,282
Accrued clinical trial expenses	1,503	(262)
Other accrued expenses	5,774	191
Liability related to refundable upfront payment	(12,500)	12,500
Deferred revenue	(28,269)	(17,615)
Other liabilities	(2,428)	(3,878)
Net cash used in operating activities	<u>(80,414)</u>	<u>(117,024)</u>
Cash flows from investing activities:		
Purchases of investments	(404,425)	(334,659)
Maturities of investments	347,743	253,682
Sales of investments	37,549	4,969
Purchases of property, plant and equipment	(9,676)	(6,392)
Net cash used in investing activities	<u>(28,809)</u>	<u>(82,400)</u>
Cash flows from financing activities:		
Payment of capital lease obligations	(5,131)	(5,945)
Proceeds from shares issued under equity compensation plans	59,522	20,287
Issuance of common stock, net of issuance costs	—	189,276
Net cash provided by financing activities	<u>54,391</u>	<u>203,618</u>
Effect of exchange rates on cash and cash equivalents	(46)	(124)
Net increase (decrease) in cash and cash equivalents	(54,878)	4,070
Cash and cash equivalents at beginning of year	59,640	55,570
Cash and cash equivalents at end of year	<u>\$ 4,762</u>	<u>\$ 59,640</u>
Supplemental disclosure of cash flow information:		
Cash paid for interest	\$ 20,116	\$ 20,589
Cash paid for income taxes	\$ 556	\$ 757

(1) The consolidated statements of cash flows for the years ended December 31, 2017 and 2016 have been derived from the audited financial statements as of those dates but do not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements.